Have a feature idea you'd love to see implemented?
Let us know!
OGEN Oragenics Inc
Price (delayed)
$0.2706
Market cap
$3.3M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$7.07
Enterprise value
$680,094
Oragenics, Inc. is focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic and the further development of effective treatments for novel antibiotics against
Highlights
Oragenics's equity has soared by 132% from the previous quarter but it has plunged by 53% YoY
The company's quick ratio has shrunk by 64% YoY but it has surged by 53% QoQ
The gross profit has dropped by 100% since the previous quarter and by 100% year-on-year
Oragenics's revenue has shrunk by 100% QoQ and by 100% YoY
Key stats
What are the main financial stats of OGEN
Market
Valuations
Earnings
Shares outstanding
12.21M
Market cap
$3.3M
Enterprise value
$680,094
Price to earnings (P/E)
N/A
Price to book (P/B)
0.49
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$19.94M
EBITDA
-$19.94M
Free cash flow
-$7.68M
Per share
Balance sheet
Liquidity
EPS
-$7.07
Free cash flow per share
-$1.18
Book value per share
$0.55
Revenue per share
$0
TBVPS
$0.8
Total assets
$5.2M
Total liabilities
$2.13M
Debt
$519,392
Equity
$3.08M
Working capital
$1.99M
Debt to equity
0.17
Current ratio
1.93
Quick ratio
1.48
Net debt/EBITDA
0.13
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-486.6%
Return on equity
-783.2%
Return on invested capital
-7,132.5%
Return on capital employed
-647.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OGEN stock price
How has the Oragenics stock price performed over time
Intraday
-6.04%
1 week
-17.73%
1 month
-21.57%
1 year
-92.27%
YTD
-95.19%
QTD
-29.01%
Financial performance
How have Oragenics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$20M
Net income
-$19.97M
Gross margin
N/A
Net margin
N/A
The gross profit has dropped by 100% since the previous quarter and by 100% year-on-year
Oragenics's revenue has shrunk by 100% QoQ and by 100% YoY
Oragenics's net income has plunged by 97% YoY and by 2.3% from the previous quarter
OGEN's operating income has dropped by 92% year-on-year
Growth
What is Oragenics's growth rate over time
Valuation
What is Oragenics stock price valuation
P/E
N/A
P/B
0.49
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
OGEN's EPS has dropped by 51% year-on-year but it is up by 6% since the previous quarter
Oragenics's equity has soared by 132% from the previous quarter but it has plunged by 53% YoY
The P/B is 83% less than the last 4 quarters average of 2.8 and 78% less than the 5-year quarterly average of 2.2
Oragenics's revenue has shrunk by 100% QoQ and by 100% YoY
Efficiency
How efficient is Oragenics business performance
The company's return on invested capital has shrunk by 74% QoQ
OGEN's ROE is down by 37% from the previous quarter
OGEN's ROA is down by 19% since the previous quarter
Dividends
What is OGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OGEN.
Financial health
How did Oragenics financials performed over time
The total assets is 145% more than the total liabilities
The total assets has soared by 92% from the previous quarter but it has contracted by 34% YoY
Oragenics's current ratio has shrunk by 65% YoY but it has surged by 65% QoQ
The debt is 83% smaller than the equity
Oragenics's equity has soared by 132% from the previous quarter but it has plunged by 53% YoY
OGEN's debt to equity has soared by 113% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.